Hemodynamic Transesophageal Ultrasound System Released Worldwide

A new hemodynamic transesophageal (TEE) system provides real-time visualization of the heart for up to 72 hours.

ImaCor, Inc. (Garden City, NY, USA), a developer of hemodynamic transesophageal echocardiography (hTEE) management devices, released the Zura EVO ultrasound system, a next-generation imaging platform that is used with ImaCor’s miniaturized, disposable ClariTEE probe.

“The EVO and ClariTEE probe are unlike conventional ultrasound in that they are built for critical care workflow, bringing direct visualization and image monitoring to intensivists. This enables hemodynamic management capabilities that reduce cost and improve quality of care.”

hTEE technology includes a purpose-built ultrasound imaging system consisting of the ClariTEE probe and Zura platform. The ClariTEE has a unique piezoelectric design with a highly efficient structure to provide quality imaging at 7 MHz with 15-cm penetration. Featuring optimized signal processing, thermal management, and Adaptaflex, the ClariTEE probe on the Zura system provides real-time visualization of the heart for up to 72 hours indwelling. This capability makes hTEE technology ideal for hemodynamic management of critically ill or injured patients over a period of time.

The new Zura EVO imaging system combines all of the intuitive components of the current Zura platform in an ergonomically compact design with a large touch screen. Additional new features include an enhanced hTEE measurement package specific to area changes of the superior vena cava, and the right and left ventricles of the heart. The Zura EVO incorporates ImaCor’s newly released software, which includes enhanced Auto-Q for optimal image quality and resolution.

“My department started the use of hTEE technology early this year,” commented Jukka Takala, MD, PhD, professor of intensive care medicine and director of the department of intensive care medicine at University Hospital Bern (Switzerland). “We were impressed with the ease of learning to use this new monitoring technology, even by intensive care specialists without prior echocardiography experience. Already the earlier version of the hTEE technology proved very helpful in patient management--we look forward with excitement to gain experience with the improved new platform.”

“Our company imperative to provide the future in critical care monitoring is realized again today through the global release of the Zura EVO,” said Peter Pellerito, president/CEO. “The EVO and ClariTEE probe are unlike conventional ultrasound in that they are built for critical care workflow, bringing direct visualization and image monitoring to intensivists. This enables hemodynamic management capabilities that reduce cost and improve quality of care.”

The Zura EVO is now commercially available.

Related Links:
ImaCor